The Hemostatic Agents Market in the Asia Pacific is expected to grow at a relatively higher CAGR. Baxter (the leading organization in the global market), plans to expand its operation in emerging nations such as India and China to enhance its accessibility. This is expected to propel the growth rate of the Asia Pacific hemostatic agents market. Meanwhile, the Europe market is likely to expand at a low CAGR due to the presence of a smaller patient pool compared to the Asia Pacific and North America.

Browse Complete Report Details:

Some of the Main Key Players Covered in the Report

Ethicon LLC.
Pfizer Inc.
Baxter International Inc.
CryoLife Inc.
Integra Life Sciences
Combination Hemostats to Dominate the Global Market

In terms of product type, the combination hemostats segment accounted for 14% of the global market in 2017. Combination hemostats are proven to be very effective and offer faster healing. Combination hemostats are capable of offering efficient hemostasis in shorter time owing to the rapid action of thrombin and gelatin. Rising adoption of combination hemostats is anticipated to drive the global hemostatic agents market during the forecast period 2018-2025.

The factors expected to drive the global hemostatic agents market are increasing the incidence of hemorrhage during surgery and a rising emphasis on blood management. Moreover, innovations in a surgical procedure such as robot-assisted surgery and rising geriatric population are anticipated to fuel the demand in global hemostatic agents market.

Request Sample PDF:

Key Segmentation:

By Product Type

Active Hemostats
Passive Hemostats
Combination Hemostats
By Application

Cardiovascular Surgery
General Surgery
Plastic Surgery
Orthopedic Surgery
Others (OBGYN, Urology, transplant, etc.)
By End User

Ambulatory Surgical Centers
Tactical Combat Casualty Care Centers
By Geography

North America
Asia Pacific
Latin America
Middle East & Africa